This phase I trial evaluates the effects of apalutamide, compared to placebo, on epidermal growth factor receptor (EGFR) protein expression in patients with non-muscle invasive bladder cancer. Apalutamide is in a class of medications called androgen receptor inhibitors. It works by blocking the effects of androgen (a male reproductive hormone) to stop the growth and spread of tumor cells. Previous studies have suggested that expression of a protein called EGFR on tumor cells is related to bladder cancer disease progression. This trial may help doctors evaluate if apalutamide has any effect on EGFR expression in patients with non-muscle invasive bladder cancer.

开始日期2025-11-01

申办/合作机构

National Cancer Institute

NCT07086651

/ RecruitingN/A

Real-world Clinical Outcomes With Androgen Receptor Pathway Inhibitors (ARPIs) in Metastatic Castration-sensitive Prostate Cancer (mCSPC) in the Flatiron Health Electronic Health Records (EHR) Database

The purpose of this study is to learn about how long apalutamide and enzalutamide are taken by men to treat mCSPC.
Prostate cancer is one of the most common cancers in men. The prostate is a gland in the male body that helps make semen. Metastatic cancer is a cancer that has spread to other parts of the body. Castration-sensitive prostate cancer means the cancer is being controlled by keeping the testosterone levels as low as would be expected if the testicles were removed by surgery.
This is a real-world study, not a clinical study. This means that researchers will look at what happens when men receive the treatments prescribed by their own doctor as part of their usual healthcare treatment. In this study, researchers will use information from cancer clinics (Flatiron Health electronic health records).
The study will include patients' information from the database for men who:
* Were identified to have mCSPC.
* Started treatment with apalutamide or enzalutamide (index date) for mCSPC.
* Were 18 years of age or older on the index date. Men in this study will be taking apalutamide or enzalutamide for treatment of their mCSPC. The study will compare how long men take apalutamide or enzalutamide. This study will use patient information from cancer clinics. Information from start of apalutamide or enzalutamide treatment until information is available in the database will be used to describe how long patients receive treatment.

开始日期2025-07-21

申办/合作机构

Pfizer Inc.

[+1]

NCT06592924

/ Recruiting临床3期IIT

A Randomized Phase III Clinical Trial for the Addition of Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response

This study is being done to answer the following question: can the chance of prostate cancer growing or spreading be lowered by adding a drug to the usual combination of drugs?
This study would like to find out if this approach is better or worse than the usual approach for prostate cancer.
The usual approach for patients who are not in a study is hormone treatment with Androgen Deprivation Therapy (ADT) and Androgen-Receptor Pathway Inhibitor (ARPI).

开始日期2025-05-28

申办/合作机构

Canadian Cancer Trials Group

[+4]

100 项与阿帕他胺相关的临床结果

登录后查看更多信息

100 项与阿帕他胺相关的转化医学

登录后查看更多信息

100 项与阿帕他胺相关的专利（医药）

登录后查看更多信息

793

项与阿帕他胺相关的文献（医药）

2025-12-31·JOURNAL OF MEDICAL ECONOMICS

Healthcare resource utilization and costs among patients with metastatic castration-sensitive prostate cancer initiated on apalutamide or enzalutamide in the United States (2019–2023)

Article

作者: Khilfeh, Ibrahim ; Bilen, Mehmet A. ; Joshi, Kruti ; Rossi, Carmine ; Du, Shawn ; Shore, Neal D. ; Lowentritt, Benjamin ; Pilon, Dominic ; Wong, Gordon ; Kinkead, Frederic ; Burbage, Sabree

AIMS:

This retrospective longitudinal cohort study compared healthcare resource utilization (HRU) and costs among patients with metastatic castration (hormone)-sensitive prostate cancer who initiated apalutamide or enzalutamide, two androgen receptor pathway inhibitors (ARPIs) that have demonstrated efficacy in the treatment of advanced prostate cancer in phase 3 clinical trials.

METHODS:

Linked patient-level data from a practice-related clinical urology database and an administrative claims database in the United States (1 January 2016-31 December 2023) were used. Per-patient-per-month (PPPM) HRU and cost outcomes were compared between the apalutamide and enzalutamide cohorts during the observation period (i.e. from ARPI initiation until continuous insurance eligibility end) after inverse probability treatment weighting to balance differences in baseline characteristics.

RESULTS:

Overall, 486 patients who initiated apalutamide (mean age 70.3 years, 53.5% white, 25.4% Black, 58.1% Medicare-insured) and 601 patients who initiated enzalutamide (mean age 70.5 years, 52.9% white, 25.5% Black, 58.8% Medicare-insured) were included. Duration of continuous treatment use was 9.6 months for apalutamide and 8.6 months for enzalutamide. Despite longer continuous ARPI use among patients treated with apalutamide relative to enzalutamide, the number of inpatient admissions (rate ratio [RR] = 0.58; 95% confidence interval [CI] = 0.37, 0.86; p = 0.012), number of admission days (RR = 0.58; 95% CI = 0.19, 0.70; p = 0.004), as well as all-cause medical costs (mean monthly cost difference = -$1,845; 95% CI = -$52, -$4,908; p = 0.044) were significantly lower in the apalutamide cohort than the enzalutamide cohort during the observation period. Mean monthly all-cause pharmacy costs between the cohorts was not significantly different ($2,121; 95% CI = -2,389, 5,703; p = 0.320).

LIMITATIONS:

This study relied on administrative claims and clinical data, which may contain coding inaccuracies or omissions. While linkages between the data sources are comprehensive, any mislinkages may have led to misclassification and information bias.

CONCLUSION:

The findings of this study suggest that apalutamide may result in better economic outcomes relative to enzalutamide.

2025-09-01·BIOMEDICAL CHROMATOGRAPHY

Quantification of Belzutifan in Biological Samples: LC–MS/MS Method Validation and Pharmacokinetic Study in Rats

Article

作者: Konidala, Sathish Kumar ; Sri, Kamma Harsha ; Puttagunta, Srinivasa Babu ; Ravisankar, Panchumarthy

ABSTRACT:

Belzutifan, an inhibitor of hypoxia inducible factor‐2α, is used to treat cancer associated with von Hippel Lindau disease. The quality control and pharmacokinetic study of this drug is crucial for effective chemotherapy. Since no bio‐analytical method has been reported, this work aimed to develop an LC–MS/MS technique for the determination of belzutifan and its application for pharmacokinetic profiling in rat plasma. Belzutifan and apalutamide (IS) were quantified on a symmetry shield (150 × 4.6 mm, 3.5 μm) column using acetonitrile and buffer (30:70% v/v) as the mobile phase, with a run time of 7 min. The spiked samples and quality controls were extracted with an optimized protein precipitation technique. Belzutifan and IS were quantified in MRM mode. The validation of the method in compliance with the US FDA's guidelines was performed. The analyte and IS were quantified at m/z 384.3422 → 311.4205 and 478.4154 → 341.1629, respectively. The results indicate linearity between 5 and 100 ng/mL concentration with r2 = 0.9997, which proved to be accurate with % recovery between 95.0% and 97.98%, along with other essential metrics within the accepted limits. The pharmacokinetic study demonstrates that the established LC–MS/MS method accurately quantifies the drugs in rat plasma and might be useful for routine quantification of belzutifan in biological matrices.

2025-08-03·JAPANESE JOURNAL OF CLINICAL ONCOLOGY

Skin rash induced by apalutamide correlated with age and relative dose intensity adjusted by body surface area in Japanese patients with prostate cancer

Article

作者: Yamasaki, Toshinari ; Hattori, Yuto ; Obayashi, Riki ; Nagoshi, Akihiko ; Yamamoto, Akihiro ; Fujiwara, Tasuku ; Igarashi, Atsushi ; Shibasaki, Noboru ; Akagi, Naoki ; Kawakita, Mutsushi

Abstract:

Objective:

Common adverse events associated with apalutamide include skin rashes and occur more frequently in Japanese patients. This study used relative dose intensity (RDI) and body surface area (BSA) to investigate the risk of skin adverse events and the efficacy of apalutamide in patients with prostate cancer.

Methods:

We retrospectively reviewed data from 63 patients with prostate cancer who were treated with an initial dose of 240 mg apalutamide, and RDI (%) was calculated. Patient backgrounds were compared, and factors contributing to rash development were analyzed. Progression-free survival (PFS), defined as the time to castration-resistant prostate cancer, was analyzed using overall RDI/BSA in metastatic castration-sensitive prostate cancer (mCSPC) patients.

Results:

The receiver operating characteristic curve analysis showed that RDI/BSA had a slightly stronger association with rash occurrence than RDI/kg. Univariate analysis identified age and RDI/BSA as significant risk factors for rash occurrence, particularly when both an age cutoff of 72 years and a RDI/BSA cutoff of 56 were met. PFS in mCSPC patients showed no significant differences among tRDI/BSA groups (<36, 36–55, >55) or between patients with and without dose reductions. Cutoff points (36 and 55) were based on the maximum tRDI/BSA values assuming continuous administration of 120 mg or 180 mg apalutamide in patients with a minimum BSA of 1.36 m2.

Conclusions:

Age and RDI/BSA were associated with rash occurrence, suggesting a need for dose reduction of apalutamide. A dose reduction to 180 or 120 mg may be appropriate in such cases when considering efficacy.

349

项与阿帕他胺相关的新闻（医药）

2025-08-12

·ioncology

European Urology丨如果转移性激素敏感性前列腺癌的治疗不再有效，下一步该怎么办？

点击上方蓝字关注我们编者按：转移性激素敏感性前列腺癌（mHSPC）是前列腺癌的关键治疗窗口，合理选择治疗方案有助于延缓疾病进展。近期，澳大利亚墨尔本莫纳什大学东部健康临床学院和东方健康临床学院的医学教授和院长Ian D. Davis教授分享了mHSPC治疗策略及其进展后选择，肿瘤瞭望-泌尿时讯特别总结，以飨读者。肿瘤学治疗的普遍原则是尽早使用最佳治疗；对于早期接受治疗的患者，通常更有可能控制治疗毒性以及肿瘤相关并发症。然而，肿瘤细胞能够适应早期治疗带来的进化压力，并且治疗在疾病后期可能会变得不那么有效。而且，治疗的机会之窗通常也相对较窄：在某些情况下，如果当时未能提供有效的治疗方案，可能意味着未来没有机会使用该方案，患者也可能永远无法从中获益。而另一种相反的观点是，联合治疗的毒性通常高于单药治疗，因此预期获益也应该高于序贯治疗。Ian D. Davis教授则认为，如果目前使用联合治疗只是“窃取”序贯治疗后期的可能获益，那么早期使用该疗法，尤其是联合治疗，可能并没有任何优势。近十年来，随着多项新型疗法及其联合方案的临床研究与实践应用，治疗策略日益丰富。基于循证医学证据的延伸策略，当某种药物在预后更差的转移性去势抵抗性前列腺癌（mCRPC）人群中证实可显著延长总生存期（OS）时，该药物通常会被纳入mHSPC的治疗探索；值得注意的是，后续研究普遍显示此类药物在mHSPC患者群体中能产生更为突出的临床获益。这一规律率先由化疗药物多西他赛的研究数据所验证，继而在雄激素受体通路抑制剂（ARPI）阿比特龙、阿帕他胺、恩扎卢胺和达罗他胺的临床试验中得到进一步确证。 ▽ 几种治疗方案在mHSPC和mCRPC的疗效差异 *非头对头比较。以各自研究的实验组和对照组进行比较。对于这些药物在mHSPC中比在mCRPC中具有明显更好获益的一个简单解释是，假设对照组的参与者无法获得后续延长生命的治疗。但事实并非如此：下表显示，各试验中的对照组患者获得后续有效治疗（在大多数情况下包括实验组使用的药物）的比例实际上更高。这些药物在mHSPC和mCRPC中的使用存在根本区别。 ▽ 转移性激素敏感性前列腺癌及后续生命延长治疗方案的关键研究 ARASENS试验是一项国际性的3期随机临床试验，旨在分析雄激素剥夺疗法（ADT）联合多西他赛的治疗方案中添加达罗他胺或安慰剂的疗效。研究人群风险相对较高：86%为同时性mHSPC，77%为CHAARTED定义的高容量疾病；根据定义，治疗医生认为ADT联合多西他赛是所有参与者合理的基线治疗方案。因此，ARASENS的受试者群体并未像其他一些ARPI mHSPC试验那样纳入预后风险分布相同的人群，但研究结果为阳性，即在ADT联合多西他赛的治疗方案中添加达罗他胺可改善OS和次要试验终点。ARASENS无法回答多西他赛是否是ADT联合达罗他胺主干治疗方案的必要补充；该问题至今仍未在3期试验中得到解答。 ARASENS试验的研究人员对后续治疗类型及其对OS的影响进行了事后分析。结果显示： 1 安慰剂组需要后续治疗的受试者数量多于达罗他胺组。 2 最常见的后续治疗是ARPI，其次是紫杉烷类药物。 3 对于最初接受达罗他胺治疗的患者，无论后续使用哪种药物，其进展后OS相似。 4 相比之下，最初接受安慰剂治疗的患者，后续治疗中ARPI带来的OS获益比后续治疗中紫杉烷类药物获益更大。 5 高容量疾病患者或多西他赛治疗后早期进展的患者在两个治疗组中的预后均较差。正如作者所述，解读结果时应谨慎，且分析存在局限性。该研究的一项结论是进展后，接受ARPI治疗的患者生存期比接受紫杉醇类药物的患者更长，但选择紫杉醇类药物而非ARPI的原因尚不清楚，但我们可以推测：报告显示，尽管基线时内脏转移的发生率在两个治疗组中相当（约为18%；这是一个分层因素），但在接受紫杉醇类药物作为后续治疗的组中，内脏转移患者的比例过高（24% vs. 接受ARPI治疗的患者为16%）。众所周知，无论接受何种治疗，这些患者的预后都更差，这可能在一定程度上解释二者之间的生存差异。进展为CRPC似乎也影响了治疗选择。作者强调，“研究治疗仅对意外的严重不良反应揭盲，对后续治疗决策不揭盲”，并且“考虑到达罗他胺的毒性有限且没有特异性副作用，研究者无法确定患者在试验期间接受了何种治疗”。然而，首次进展后的治疗存在严重不平衡：在最初接受达罗他胺治疗后需要后续治疗的患者中，63%接受了ARPI治疗，29%接受了紫杉醇治疗；而在最初接受安慰剂治疗的患者中，78%随后接受了ARPI治疗，19%接受了紫杉醇治疗。研究结果显示，如果进展事件是PSA进展，则首次进展后的治疗更有可能是ARPI，而如果有放射学或临床进展的证据，则更有可能使用紫杉醇治疗，无论初始治疗组如何。通常不建议更换ARPI，因此，这些影响mCRPC进展初始和后续治疗选择的因素，也可能解释了ARPI作为mCRPC进展首选治疗方案时，相对于紫杉醇类药物，其优势显而易见。mHSPC的初始治疗类型是否会影响CRPC的进一步治疗？ Ian D. Davis教授完全同意研究人员的观点，“进展后治疗方案的制定应考虑疾病规模和不同作用机制的药物”。但Ian D. Davis教授并不确信这项分析能够证明ARPI一定是mHSPC治疗进展后mCRPC的最佳首选治疗方案，尤其是在既往使用过ARPI的情况下；但如果患者从未接受过ARPI治疗，ARPI也是一个不错的选择。最终的生存率改善需要我们充分利用患者可能获得的每一个获益机会。首先要使用最佳治疗方案，但也要考虑患者以后可能需要什么，以及按照什么顺序进行治疗，并确保最大限度地为患者提供从未来可能接受的任何治疗中受益的机会。参考文献上下滑动查看更多内容 [1]. Davis I D. If the Treatment for Metastatic Hormone-sensitive Prostate Cancer Stops Working, What Next?[J]. European Urology, 2025. [2]. Sweeney CJ, Chen YH, Carducci M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med 2015;373:737–46. [3]. James ND, Sydes MR, Clarke NW, et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet 2016;387:1163–77. [4]. Fizazi K, Tran N, Fein L, et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med 2017;377:352–60. [5]. James ND, de Bono JS, Spears MR, et al. Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med 2017;377:338–51. [6]. Chi KN, Agarwal N, Bjartell A, et al. Apalutamide for metastatic, castration-sensitive prostate cancer. N Engl J Med 2019;381:13–24. [7]. Armstrong AJ, Szmulewitz RZ, Petrylak DP, et al. ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer. J Clin Oncol 2019;32:2974–86. [8]. Davis ID, Martin AJ, Stockler MR, et al. Enzalutamide with standard first-line therapy in metastatic prostate cancer. N Engl J Med 2019;381:121–31. [9]. Sweeney CJ, Martin AJ, Stockler MR, et al. Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial. Lancet Oncol 2023;24:323–34. [10]. Smith MR, Hussain M, Saad F, et al. Darolutamide and survival in metastatic, hormone-sensitive prostate cancer. N Engl J Med 2022;386:1132–42. [11]. Grimm M-O, Smith M, Hussain M, et al. Postprogression survival of patients with metastatic hormone-sensitive prostate cancer who received darolutamide or placebo in combination with docetaxel and androgen deprivation therapy: post hoc analysis of the phase 3 ARASENS trial. Eur Urol. In press. [12]. de Wit R, de Bono J, Sternberg CN, et al. Cabazitaxel versus abiraterone or enzalutamide in metastatic prostate cancer. N Engl J Med 2019;381:2506–18. Ian D. Davis 教授澳大利亚墨尔本莫纳什大学东部健康临床学院和东方健康临床学院的医学教授和院长肿瘤内科医生主要临床兴趣是泌尿系统癌症，研究兴趣是癌症免疫学和泌尿系统癌症的生物学维多利亚癌症委员会医学和科学委员会和研究常设小组委员会成员创立了澳大利亚临床肿瘤学会（COSA）泌尿肿瘤学组，COSA理事会成员，曾任COSA董事会董事澳大利亚和新西兰泌尿生殖系统和前列腺癌试验组有限公司（ANZUP）的创始人，并担任ANZUP董事会及其科学顾问委员会主席（来源：《肿瘤瞭望-泌尿时讯》编辑部）声明凡署名原创的文章版权属《肿瘤瞭望》所有，欢迎分享、转载。本文仅供医疗卫生专业人士了解最新医药资讯参考使用，不代表本平台观点。该等信息不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议，如果该信息被用于资讯以外的目的，本站及作者不承担相关责任。

临床3期

2025-07-31

·米内网

【火热】暴涨119%复方止吐药，科伦拿下首仿

精彩内容7月30日，国家药监局官网显示，科伦药业的奈妥匹坦帕洛诺司琼胶囊、小儿复方氨基酸注射液(19AA-Ⅰ)获批上市、视同过评。奈妥匹坦帕洛诺司琼胶囊为复方止吐药，科伦拿下该品种首仿；小儿复方氨基酸注射液(19AA-Ⅰ)属于儿童复方胃肠外营养输液，科伦为第三家获批过评。奈妥匹坦帕洛诺司琼胶囊是全球首款同时阻断5-HT3受体和NK-1受体双通道的口服复方药物，用于预防高度致吐性化疗引起的急性/延迟性恶心和呕吐，目前已纳入国家医保乙类药目录。在医保助力下，奈妥匹坦帕洛诺司琼胶囊市场快速成长，其2022-2024年在中国三大终端六大市场（统计范围详见本文末）销售额涨幅分别达389.15%、421.89%和119.89%；2025Q1继续以71.18%的增速增长至近1亿元，全年有望向超4亿元的目标发起冲击。近年来中国三大终端六大市场奈妥匹坦帕洛诺司琼胶囊销售趋势（单位：万元）来源：米内网格局数据库目前，奈妥匹坦帕洛诺司琼胶囊已有原研厂商Helsinn Healthcare的产品获批在售。近日，该品种先后迎来2家本土药企冲线，分别是科伦药业和齐鲁制药；另有浙江康莱特药业以新分类报产在审，获批上市即视同过评。小儿复方氨基酸注射液(19AA-Ⅰ)是专为儿童设计的胃肠外营养复方制剂，主要为早产儿、低体重儿及无法经口摄入蛋白质或摄入量不足的新生儿，提供生长发育的必需和非必需氨基酸等。在中国三大终端六大市场，小儿复方氨基酸注射液(19AA-Ⅰ)近年来销售额均保持在2.5-2.7亿元之间；从渠道格局上看，城市公立医院常年高居第一，市场份额均在60%以上，县级公立医院位居其后，市占比均超23%。米内网数据显示，小儿复方氨基酸注射液(19AA-Ⅰ)已有5家企业拥有生产批文；其中华润双鹤药业以补充申请获批过评，内蒙古白医制药、科伦药业分别以新3类报产获批、视同过评；津药和平制药、湖北民康药业、北京仁众药业等6家企业均以新分类提交上市申请，目前正处审评审批阶段。小儿复方氨基酸注射液(19AA-Ⅰ)一致性评价企业申报情况来源：米内网一致性评价进度数据库今年以来，科伦药业已有40多个高端仿制药获批上市，涵盖心脑血管系统药物、消化系统及代谢药、全身用抗感染药物等治疗大类；其中，奈妥匹坦帕洛诺司琼胶囊、芦曲泊帕片、注射用亚胺培南西司他丁钠/氯化钠注射液、注射用比阿培南/氯化钠注射液等为国内首仿+首家过评，阿帕他胺片、枸橼酸钠血滤置换液、注射用头孢他啶/氯化钠注射液等为国产第2家获批，复方氨基酸注射液(18AA-Ⅸ)、他克莫司缓释胶囊、昂丹司琼口溶膜、复方电解质醋酸钠注射液等为国产第3家获批。资料来源：米内网数据库、国家药监局官网注：米内网《中国三大终端六大市场药品竞争格局》，统计范围是：城市公立医院和县级公立医院、城市社区中心和乡镇卫生院、城市实体药店和网上药店，不含民营医院、私人诊所、村卫生室，不含县乡村药店；上述销售额以产品在终端的平均零售价计算。数据统计截至7月31日，如有疏漏，欢迎指正！免责声明：本文仅作医药信息传播分享，并不构成投资或决策建议。本文为原创稿件，转载文章或引用数据请注明来源和作者，否则将追究侵权责任。投稿及报料请发邮件到872470254@qq.com稿件要求详询米内微信首页菜单栏商务及内容合作可联系QQ：412539092【分享、点赞、在看】点一点不失联哦

上市批准一致性评价

2025-07-27

·ioncology

ESMO 2025丨59项中国泌尿肿瘤研究入选ESMO大会，一文畅览

点击蓝字，关注我们编者按：2025年欧洲肿瘤内科学会（ESMO）年会将于10月17日~21日在德国柏林召开。作为肿瘤学界的年度盛典，ESMO每年都会吸引上万名世界各地的肿瘤学大咖，为全球学者提供了良好的交流平台。目前公布的摘要标题中，入选的中国泌尿肿瘤研究数量再创新高，达到59篇，在此邀您共赏~口头报告摘要号：2592MO英文标题：Fruquintinib (FRUQ) plus sintilimab (SIN) versus axitinib (AXI) or everolimus (EVE) monotherapy as 2L treatment in pts with locally advanced or metastatic renal cell carcinoma (RCC)： results from phase 3 part of a randomized, open-label, active-controlled phase 2/3 study (FRUSICA-2)中文标题：呋喹替尼联合信迪利单抗对比阿昔替尼或依维莫司单药治疗局部晚期或转移性肾细胞癌患者的2L治疗：随机、开放标签、活性药物对照2/3期研究的3期部分结果（FRUSICA-2）讲者：叶定伟教授复旦大学附属肿瘤医院当地时间：Fri, 17.10.2025 16：00 - 17：30地点：Karlsruhe Auditorium - Hall 5.2摘要号：2598MO英文标题：The Intratumor Mycobiome Promotes Clear Cell Renal Cell Carcinoma Progression via Neutrophil-Mediated Immune Suppression中文标题：肿瘤内真菌群通过中性粒细胞介导的免疫抑制促进透明细胞肾细胞癌进展讲者：Kangli Ma 中国上海当地时间：Sun, 19.10.2025 08:30 - 10:00地点：Bonn Auditorium - Hall 7.1c摘要号：3071MO英文标题：Disitamab Vedotin plus Tislelizumab as Nephron-Sparing Therapy for High-Risk Upper Tract Urothelial Carcinoma： The Phase II DISTINCT-I Trial中文标题：维迪西妥单抗联合替雷利珠单抗作为高危上尿路尿路上皮癌的肾单位保留疗法：II 期 DISTINCT-I 临床试验讲者：黄吉炜教授上海交通大学医学院附属仁济医院当地时间：Sun, 19.10.2025 08:30 - 10:00地点：Bonn Auditorium - Hall 7.1c前列腺癌及阴茎癌壁报摘要号：1055P英文标题：Neoadjuvant and/or adjuvant immune checkpoint inhibitors combined with chemotherapy for locally advanced resectable penile squamous cell carcinoma中文标题：新辅助和/或辅助免疫检查点抑制剂联合化疗治疗局部晚期可切除阴茎鳞状细胞癌讲者：Zhao Zhigang 中国天津摘要号：2431P英文标题：The impact of lead-in androgen-deprivation therapy (ADT) on severe neutropenia (grade≥3) caused by docetaxel in patients with metastatic, hormone-sensitive prostate cancer(mHSPC)： A Post Hoc Analysis of ARASENS中文标题：转移性激素敏感前列腺癌（mHSPC）患者引入雄激素剥夺疗法（ADT）对多西他赛所致重度中性粒细胞减少症（≥3级）的影响：ARASENS的事后分析讲者：Yufan Y. Zhao 中国上海摘要号：2434P英文标题：The efficacy of rezvilutamide (Rez) plus androgen-deprivation therapy (ADT) in patients (pts) with high-volume, nonvisceral metastatic hormone-sensitive prostate cancer (HSPC)： a post hoc analysis of CHART study中文标题：瑞维鲁胺联合雄激素剥夺疗法（ADT）对高容量非内脏转移性激素敏感性前列腺癌（HSPC）患者的疗效：CHART研究的事后分析讲者：戴波教授复旦大学附属肿瘤医院摘要号：2435P英文标题：Predictive value of HSD3B1 germline single nucleotide polymorphism rs1047303 for hormone therapy outcomes in Chinese prostate cancer patients中文标题：HSD3B1种系单核苷酸多态性rs1047303对中国前列腺癌患者激素治疗结局的预测价值讲者：Ruofan Shi 中国上海摘要号：2436P英文标题：Efficacy and Safety of All-Site Radiation Therapy and Standard of Care Therapy with or without Docetaxel for Hormone-Sensitive High Gleason Score Prostate Cancer： 6-Year Results from a Long-Term Study中文标题：全部位放射治疗和标准治疗联合或不联合多西他赛治疗高格里森评分的激素敏感性前列腺癌的疗效和安全性：一项长期研究的6年结果讲者：Huizhu Chen 中国北京摘要号：2439P英文标题：Two-year Outcomes in Very High-Risk Localized Prostate Cancer Following Neoadjuvant Therapy with Poly(ADP-ribose) Polymerase Inhibitors and Abiraterone： A Pooled Post-Hoc Analysis of Two Prospective Trials中文标题：极高危局限性前列腺癌患者接受PARP抑制剂联合阿比特龙新辅助治疗后的两年疗效：两项前瞻性试验的汇总事后分析讲者：Tingwei Zhang 中国上海摘要号：2449P英文标题：CHAMPION study (NCT05717582) ： a prospective study of maximal-cytoreductive therapies for patients with de novo metastatic hormone-sensitive prostate cancer who achieve oligopersistent metastases during systemic treatment with apalutamide plus androgen deprivation therapy中文标题：CHAMPION研究：一项针对在接受阿帕他胺联合雄激素剥夺疗法全身治疗期间出现寡持续性转移的原发转移性激素敏感性前列腺癌患者的最大细胞减灭疗法的前瞻性研究讲者：Jian Pan 中国上海摘要号：2450P英文标题：Phase 1 study of QLH12016, an androgen receptor (AR) PROTAC degrader in heavily pretreated patients with metastatic castration-resistant prostate cancer (mCRPC)： safety, tolerability, and antitumor activity中文标题：雄激素受体（AR）PROTAC降解剂QLH12016在转移性去势抵抗性前列腺癌（mCRPC）患者中开展的I期临床试验：安全性、耐受性和抗肿瘤活性讲者：张顺教授南京鼓楼医院摘要号：2453P英文标题：Rezvilutamide (REZ) in combination with androgen-deprivation therapy (ADT) for prostate cancer patients with biochemical recurrence (BCR) post radical prostatectomy (RP)： preliminary results from a phase 2 trial中文标题：瑞维鲁胺联合雄激素剥夺疗法（ADT）治疗根治性前列腺切除术（RP）后生化复发（BCR）的前列腺癌患者：一项2期临床试验的初步结果讲者：邱雪峰教授南京鼓楼医院摘要号：2454P英文标题：RAPID trial (NCT06251492)： Radiation and Adebrelimab in Metastatic Castration Resistant Prostate Cancer with Imaging-Measurable Disease中文标题：RAPID试验：放疗和阿得贝利单抗治疗伴影像学可测量病变的转移性去势抵抗性前列腺癌讲者：Yu Wei 中国上海摘要号：2456P英文标题：Olaparib Plus Abiraterone in HRR-Mutated Metastatic Hormone-Sensitive Prostate Cancer中文标题：奥拉帕利联合阿比特龙治疗HRR突变转移性激素敏感性前列腺癌讲者：庄君龙教授南京鼓楼医院摘要号：2466P英文标题：Sodium-glucose cotransporter 2 inhibitors use in prostate cancer patients undergoing hormone therapy： a sequential target trial emulation study中文标题：钠-葡萄糖协同转运蛋白2抑制剂在接受激素治疗的前列腺癌患者中的应用：序贯靶向试验模拟研究讲者：Ruofan Shi 中国香港摘要号：2476P英文标题：Neoadjuvant darolutamide plus ADT for High/Very-high risk locally advanced PCa： a multi-center, open label, single arm, phase 2 trial中文标题：达罗他胺联合ADT新辅助治疗高危/极高危局部晚期前列腺癌：一项多中心、开放标签、单组、2期临床试验讲者：Kaiwei Yang 中国北京摘要号：2480P英文标题：A Randomized Controlled Clinical Trial on Autologous Vas Deferens Sling Suspension of the Vesicourethral Anastomosis to Improve Early Urinary Control After Retzius-sparing Robotic-assisted Radical Prostatectomy中文标题：自体输精管悬吊带悬吊膀胱尿道吻合口改善保留Retzius的机器人辅助根治性前列腺切除术后早期排尿控制的随机对照临床试验讲者：ZhiYuan Yang 中国南京摘要号：2481P英文标题：Pathological and Clinical Characteristics of Prostate Biopsy Cases with PSA Levels Below 4.0 ng/mL： A Multicenter Retrospective Real-World Study (YHCG-003 Study)中文标题：PSA水平低于4.0 ng/mL的前列腺穿刺活检病例的病理和临床特征：一项多中心回顾性真实世界研究（YHCG-003研究）讲者：苏瑞教授宁波大学附属第一医院摘要号：2482P英文标题：The Role of Sustained Serum Sodium Levels in Prognostication of Metastatic Prostate Cancer： Findings from Global Phase III Trials中文标题：血清钠水平持续在转移性前列腺癌预后中的作用：来自全球III期临床试验的结果讲者：倪旭栋教授复旦大学附属肿瘤医院摘要号：2486P英文标题：Quality of Life Analysis in Patients with High-Risk Localized Prostate Cancer Receiving Neoadjuvant Pamiparib plus Abiraterone and ADT： A Prospective Study中文标题：接受帕米帕利联合阿比特龙及ADT新辅助治疗的高危局限性前列腺癌患者生活质量分析：一项前瞻性研究讲者：Tangtao Gong 中国南京摘要号：2487P英文标题：Clinical Management Strategies and Long-Term Outcomes in Patients with Atypical Small Acinar Proliferation Diagnosed via Prostate Biopsy： A Collaborative Multicenter Real-World Study by Urologists and Pathologists (YHCG-002 Study)中文标题：前列腺穿刺活检确诊为非典型小腺泡增生患者的临床管理策略及长期疗效：一项泌尿科医生与病理科医生合作开展的多中心真实世界研究（YHCG-002研究）讲者：马琪教授宁波大学附属第一医院摘要号：2494P英文标题：Interim Analysis of a Prospective, Non-Randomized Controlled Study： Comparison of the Efficacy and Safety of ADT + Docetaxel vs. ADT + Novel Hormone Therapy in High Gleason Score Non-Metastatic Prostate Cancer Patients Receiving Radiotherapy中文标题：前瞻性、非随机对照研究的中期分析：ADT+多西他赛对比ADT+新型激素疗法在接受放射治疗的高Gleason评分非转移性前列腺癌患者中的疗效和安全性比较讲者：Mingwei Ma 中国北京摘要号：2523eP英文标题：Preclinical pharmacokinetic and pharmacodynamic study of GS24-B039, a 3-month long-acting abiraterone prodrug中文标题：疗效长达3个月的阿比特龙药物前体GS24-B039的临床前药代动力学和药效学研究讲者：Yujie Zhang 中国成都摘要号：2527eP英文标题：Baseline 68Ga-PSMA PET-CT for treatment monitoring of neoadjuvant prostate cancer： a diagnostic evaluation中文标题：用于前列腺癌新辅助治监测的68Ga-PSMA PET-CT基线：诊断评估讲者：Qing Zhang 中国南京摘要号：2530eP英文标题：HER2 Expression Dynamics and Prognostic Value in matched Hormone-Sensitive and Castration-Resistant Prostate Cancer Lesions中文标题：HER2在匹配的激素敏感性和去势抵抗性前列腺癌病变中的表达动态和预后价值讲者：Yelin Mulati 中国北京尿路上皮癌壁报摘要号：3075P英文标题： Circulating and Urine Tumor DNA Dynamics Predict Minimal Residual Disease and Guide Adjuvant Therapy in Locally Advanced Upper Tract Urothelial Carcinoma (CURATE-UTUC)： A Multicenter Prospective Longitudinal Cohort Study中文标题：循环和尿液肿瘤DNA动态预测局部晚期上尿路尿路上皮癌的微小残留病灶并指导辅助治疗（CURATE-UTUC）：一项多中心前瞻性纵向队列研究讲者：黄吉炜教授上海交通大学医学院附属仁济医院摘要号：3076P英文标题： Final results of a multi-center phase Ib/II study of RC48-ADC combined with tislelizumab as neoadjuvant treatment in patients with HER2 positive locally advanced muscle-invasive urothelial bladder cancer（Hope-03）中文标题：RC48-ADC联合替雷利珠单抗治疗HER2阳性局部晚期肌层浸润性膀胱癌患者的多中心Ib/II期临床研究最终结果（Hope-03）讲者：Feng Wen 中国成都摘要号：3079P英文标题： Efficacy and safety results from Formula-01： a phrase II study of Disitamab Vedotin plus BCG in HER2 high expression high-risk non-muscle invasive bladder cancer patients (HR-NMIBC)中文标题：Formula-01的疗效和安全性结果：维迪西妥单抗联合BCG治疗HER2高表达高危非肌层浸润性膀胱癌患者（HR-NMIBC）的II期临床讲者：Xingliang Tan 中国广州摘要号：3085P英文标题： PUNCH02： Interim results from a phase II study of tislelizumab combined with disitamab vedotin as a bladder preservation therapy for urine tumor DNA (utDNA)-defined clinical complete response (cCR) MIBC patients中文标题：PUNCH02：替雷利珠单抗联合维迪西妥单抗用于治疗尿液肿瘤DNA（utDNA）定义的临床完全缓解（cCR）MIBC患者的膀胱保留疗法的II期临床中期结果讲者：Bin Huang 中国成都摘要号：3086P英文标题： A Phase 2 Study of Organ-Preserving Therapy and Liquid Biopsy-Based Response Monitoring in Locally Advanced Muscle-Invasive Bladder Cancer中文标题：局部晚期肌层浸润性膀胱癌器官保留治疗及基于液体活检疗效监测的II期研究讲者：Jiani Deng 中国成都摘要号：3097P英文标题： Build an Artificial Intelligence Prediction Model Based on Deep Learning Technology to Predict the Muscular Invasion of Urothelial Carcinoma Preoperatively中文标题：基于深度学习技术构建人工智能预测模型，术前预测尿路上皮癌肌层浸润情况讲者：Sheng Xie 中国南充摘要号：3098P英文标题： Fibroblast Growth Factor Receptor 3 (FGFR3) - Driven Genomic Landscape and the Impact on Clinical Outcomes of Fexagratinib (Fexa) in Chinese metastatic or unresectable Urothelial Carcinoma (mUC)中文标题：成纤维细胞生长因子受体3（FGFR3）-驱动的基因组特征以及Fexagratinib对中国转移性或不可切除尿路上皮癌（mUC）临床结局的影响讲者：叶定伟教授复旦大学附属肿瘤医院摘要号：3099P英文标题： Proteogenomic characterization of the non-muscle-invasive bladder cancer response to BCG reveals potential therapeutic strategies中文标题：非肌层浸润性膀胱癌对BCG反应的蛋白质组学表征揭示了潜在的治疗策略讲者：Maoping Cai 中国上海摘要号：3103P英文标题： Chemotherapy plus Toripalimab as Neoadjuvant Therapy for Locally Advanced Upper Tract Urothelial Carcinoma： Mid-term Results from the Phase II, Multi-center Study (WUTSUP-01)中文标题：化疗联合特瑞普利单抗作为局部晚期上尿路尿路上皮癌的新辅助治疗：II期多中心临床研究（WUTSUP-01）的中期结果讲者：Kai Chen 中国成都摘要号：3110eP英文标题： Cost-Effectiveness of ctDNA-Guided Atezolizumab Adjuvant Therapy for High-Risk Muscle-Invasive Urothelial Carcinoma中文标题：ctDNA指导下的阿替利珠单抗辅助治疗高危肌层浸润性尿路上皮癌的成本效益讲者：Zihan Xue 中国天津摘要号：3114eP英文标题： Changes in Circulating Tumor Cells (CTCs) and HER-2 Expression as Indicators of Efficacy and Recurrence Prediction in Neoadjuvant Disitamab Vedotin (DV) Plus Toripalimab Treatment for Muscle-Invasive Bladder Cancer (MIBC)： Updated Data and Preliminary Outcomes for Recurrence中文标题：循环肿瘤细胞（CTC）及HER-2表达变化作为新辅助维迪西妥单抗联合特瑞普利单抗治疗肌层浸润性膀胱癌（MIBC）疗效及复发预测指标：最新数据及复发初步结果讲者：Yudong Cao 中国北京摘要号：3125eP英文标题： Kidney-Sparing Approach for Selected Localized High-Risk Upper Tract Urothelial Carcinoma： A Pilot Study Combining Endoscopic Thulium Laser Ablation with Perioperative Disitamab Vedotin and Immune Checkpoint Inhibitors中文标题：选择性局限性高危上尿路尿路上皮癌的肾脏保留疗法：内镜铥激光消融术联合围手术期维迪西妥单抗及免疫检查点抑制剂的初步研究讲者：Qihao Wang 中国成都摘要号：3127eP英文标题： Bulumtatug Fuvedotin (BFv 9MW2821), a novel Nectin-4 antibody-drug conjugate(ADC), combined with Toripalimab in patients with locally advanced or metastatic urothelial carcinoma(la/mUC)： Follow-up results from a phase 1b/2 study.中文标题：Bulumtatug Fuvedotin（BFv 9MW2821），一种新型Nectin-4抗体偶联药物（ADC），与特瑞普利单抗联合治疗局部晚期或转移性尿路上皮癌（la/mUC）患者：1b/2期研究的后续结果讲者：Shusuan Jiang 中国长沙肾癌壁报摘要号：2602P英文标题：Safety and efficacy of iparomlimab and tuvonralimab (QL1706) plus lenvatinib in previously untreated patients with clear cell renal cell carcinoma： results from a phase 1b study中文标题：艾帕洛利托沃瑞利单抗（QL1706）联合仑伐替尼治疗未经治疗的透明细胞肾细胞癌患者的安全性和有效性：一项1b期研究的结果讲者：董培中山大学肿瘤防治中心摘要号：2608P英文标题：Early detection of renal cell carcinoma： A novel cfDNA fragmentomics-based liquid biopsy assay.中文标题：肾细胞癌的早期检测：一种基于cfDNA片段组学的新型液体活检检测方法讲者：彭毓璐教授中山大学肿瘤防治中心摘要号：2615P英文标题：Belzutifan Plus Lenvatinib For Chinese Participants (pts) With Previously Treated Advanced Clear Cell Renal Cell Carcinoma (ccRCC)： Updated Results of Cohort 1 of the LITESPARK-010 Study中文标题：贝组替凡联合仑伐替尼治疗既往接受过治疗的晚期透明细胞肾细胞癌（ccRCC）中国患者：LITESPARK-010研究队列1更新结果讲者：盛锡楠教授北京大学肿瘤医院摘要号：2621P英文标题：Efficacy and safety of adjuvant penpulimab in very high-risk clear cell renal cell carcinoma： a prospective, controlled, phase II study中文标题：派安普利单抗辅助治疗极高危透明细胞肾细胞癌的疗效和安全性：一项前瞻性、对照、II期研究讲者：顾良友教授中国人民解放军总医院摘要号：2623P英文标题：CLEAR-IT： Preliminary Results from a Phase II Study Evaluating Cadonilimab Plus Lenvatinib in Previously Immunotherapy-Treated Advanced/Metastatic Clear Cell Renal Cell Carcinoma (ccRCC)中文标题：CLEAR-IT：卡度尼利单抗联合仑伐替尼治疗既往接受过免疫疗法治疗的晚期/转移性透明细胞肾细胞癌（ccRCC）的II期临床研究的初步结果讲者：黄吉炜教授上海交通大学医学院附属仁济医院摘要号：2630P英文标题：Single-Nucleus Atlas of Collecting Duct Carcinoma Reveals Cellular Heterogeneity, Malignant Evolution, and Immunosuppressive Microenvironment中文标题：集合管癌单核图谱揭示细胞异质性、恶性演化和免疫抑制微环境讲者：Linhui Zhang 中国上海摘要号：2634P英文标题：Remodeling of the tumor microenvironment by PD-1 blockade plus tyrosine kinase inhibitor in advanced renal cell carcinoma中文标题：PD-1阻断联合酪氨酸激酶抑制剂对晚期肾细胞癌肿瘤微环境的重塑讲者：Qiyang Liang 中国北京摘要号：2638P英文标题：Anlotinib plus everolimus as first-line treatment for advanced non–clear cell renal cell carcinoma：1 year updated results from UC-001, a single-center, single-arm, phase II trial中文标题：安罗替尼联合依维莫司作为晚期非透明细胞肾细胞癌的一线治疗：单中心、单组、II 期临床试验UC-001的1年更新结果讲者：徐文浩教授复旦大学附属肿瘤医院摘要号：2640P英文标题：A multimodal multifaceted artificial intelligence model for diagnosing renal masses using contrast-enhanced computed tomography and laboratory parameters： A multicenter study中文标题：基于增强CT和实验室参数诊断肾脏肿块的多模态多方面人工智能模型：一项多中心研究讲者：Axide Haoni 中国上海摘要号：2642P英文标题：Immunosuppressive TREM2⁺ Tumor-Associated Macrophages Potentiate Immunotherapy Responsiveness in Patients with Clear Cell Renal Cell Carcinoma (ccRCC)中文标题：免疫抑制TREM2⁺肿瘤相关巨噬细胞增强透明细胞肾细胞癌（ccRCC）患者的免疫治疗反应讲者：Jiahao Wang 中国上海摘要号：2648P英文标题：Phase II Clinical Study of the Safety and Efficacy of Sintilimab in Combination with Axitinib and Stereotactic Radiotherapy in the Treatment of Local-regional Recurrent Renal Cell Carcinoma中文标题：信迪利单抗联合阿昔替尼及立体定向放射治疗治疗局部区域复发性肾细胞癌的安全性和有效性的II期临床研究讲者：Ruiqi Liu 中国广州摘要号：2653eP英文标题： Why Is TFE3 Prone to Breakage in TFE3-Rearranged Renal Cell Carcinoma? A Perspective on Non-Canonical DNA Structures and Their Stability中文标题：为什么TFE3在TFE3重排的肾细胞癌中容易断裂？非经典DNA结构及其稳定性的视角讲者：Xiaopo Zhang 中国南京摘要号：2654eP英文标题： Multi-Omic Analysis of Collecting Duct Carcinoma Reveals Enhanced Ribosome Biogenesis as a Driver of Malignant Metastasis and Proliferation中文标题：集合管癌的多组学分析揭示增强的核糖体生物合成是恶性转移和增殖的驱动因素讲者：Linhui Zhang 中国上海摘要号：2657eP英文标题： Deciphering Immune microenvironment landscape in renal cell carcinoma with different regimen：a single cell RNA sequencing study中文标题：解读不同治疗方案肾细胞癌的免疫微环境：单细胞RNA测序研究讲者：Jiahao Wang 中国上海摘要号：2660eP英文标题： Clinical Value of Dynamic ctDNA-MRD Monitoring in Advanced mRCC Patients Receiving TKIs Plus PD-1 Inhibitor Therapy中文标题：动态ctDNA-MRD监测在接受TKI联合PD-1抑制剂治疗的晚期mRCC患者中的临床价值讲者：黄吉炜教授上海交通大学医学院附属仁济医院摘要号：2661eP英文标题： Multi-omics Uncovers the Molecular Machinery Underlying Autophagic Regulation Leading to Metastasis in Chromophobe Renal Cell Carcinoma中文标题：多组学揭示导致嫌色性肾细胞癌转移的自噬调控的分子机制讲者：Jiayi Lu 中国上海摘要号：2670eP英文标题： SPP1+ Tumor-associated Macrophages Drive Immunotherapy Resistance via CD8+ T Cell Dysfunction in Clear Cell Renal Cell Carcinoma中文标题：SPP1+肿瘤相关巨噬细胞通过透明细胞肾细胞癌中的CD8+T细胞功能障碍驱动免疫治疗耐药性讲者：Wenbin Jiang 中国上海摘要号：2675eP英文标题： Shared Genetic and Proteomic Architecture Between Metabolic Syndrome and Renal Cell Carcinoma Highlights Insulin Resistance-CKD Axis中文标题：代谢综合征与肾细胞癌之间共享的遗传和蛋白质组学结构突出了胰岛素抵抗-CKD轴讲者：Chenhao Xu 中国成都摘要号：2676eP英文标题： Schwann Cell-Mediated Mechanisms in Renal Cell Carcinoma Metastasis at the Tumor Border Microenvironment中文标题：肾细胞癌在肿瘤边界微环境中转移的施万细胞介导机制讲者：Qiang Song 中国上海摘要号：2679eP英文标题：CT-based intratumoral vascular feature reveals a transcriptomic signature predictive of prognosis and treatment stratification in renal cell carcinoma中文标题：基于CT的肿瘤内血管特征揭示了可预测肾细胞癌预后和治疗分层的转录组特征讲者：Zilin Wang 中国成都相关研究信息来自ESMO官网。本文主要按照肿瘤类型和摘要号进行排序，如有遗漏和错误，欢迎留言~（来源：《肿瘤瞭望-泌尿时讯》编辑部）声明凡署名原创的文章版权属《肿瘤瞭望》所有，欢迎分享、转载。本文仅供医疗卫生专业人士了解最新医药资讯参考使用，不代表本平台观点。该等信息不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议，如果该信息被用于资讯以外的目的，本站及作者不承担相关责任。

临床结果临床2期临床3期

100 项与阿帕他胺相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D11040	阿帕他胺	L02BB05	DB11901

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
转移性前列腺癌	日本	Janssen Pharmaceutical KK	2020-05-29
转移性去势抵抗性前列腺癌	美国	Janssen Biotech, Inc.	2019-09-17
激素依赖性前列腺癌	欧盟	Janssen-Cilag International NV	2019-01-14
激素依赖性前列腺癌	冰岛	Janssen-Cilag International NV	2019-01-14
激素依赖性前列腺癌	列支敦士登	Janssen-Cilag International NV	2019-01-14
激素依赖性前列腺癌	挪威	Janssen-Cilag International NV	2019-01-14
前列腺癌	加拿大	Janssen Research & Development LLC	2018-07-27
去势敏感前列腺癌	澳大利亚	Janssen-Cilag Pty Ltd.	2018-07-05
去势抵抗性前列腺癌	美国	Janssen Biotech, Inc.	2018-02-14

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
前列腺腺癌	临床3期	中国香港	Janssen LP	2020-07-20
复发性前列腺癌	临床3期	中国香港	Janssen LP	2020-07-20
非转移性前列腺癌	临床3期	法国	Janssen Pharmaceutica NV	2020-01-09
阿尔茨海默症	临床3期	美国	西安杨森制药有限公司	2015-12-07
阿尔茨海默症	临床3期	美国	Janssen Research & Development LLC	2015-12-07
阿尔茨海默症	临床3期	美国	Aragon Pharmaceuticals, Inc.	2015-12-07
阿尔茨海默症	临床3期	日本	Janssen Research & Development LLC	2015-12-07
阿尔茨海默症	临床3期	日本	Aragon Pharmaceuticals, Inc.	2015-12-07
阿尔茨海默症	临床3期	日本	西安杨森制药有限公司	2015-12-07
阿尔茨海默症	临床3期	阿根廷	西安杨森制药有限公司	2015-12-07

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03298087 (CTgov)	临床2期	寡转移性前列腺癌	28	stereotactic body radiotherapy+apalutamide+Abiraterone+Leuprolide	淵壓顧鑰夢觸範醖顧願 = 壓獵窪網鑰積廠顧築壓糧積觸獵鹽餘夢構衊醖 (製糧願選蓋鏇衊簾遞選, 餘觸淵範醖窪淵憲簾構 ~ 製憲選夢鹽顧夢網衊膚) 更多	-	2025-08-01
NCT03412396 (CTgov)	临床2期	前列腺腺癌	45	Apalutamide	蓋夢遞積簾衊糧積衊蓋 = 餘範鹽窪淵襯艱襯齋築齋夢鹹鑰衊憲積糧網網 (鏇鹹鹽艱簾醖積網窪襯, 願淵艱襯鹹醖襯網繭簾 ~ 簾簾遞衊繭顧齋夢顧鏇) 更多	-	2025-07-03
ASCO2025	N/A	激素依赖性前列腺癌 PSA kinetics	129	Apalutamide plus ADT	鑰齋製餘積網簾鏇淵衊(鹹製餘憲築糧顧餘構構) = 願鬱選醖糧鏇積築蓋壓壓鑰襯鑰蓋鹽憲觸壓窪 (鹽鏇選鬱鹽餘憲夢積繭 ) 更多	积极	2025-05-30
NCT04926181 (CTgov)	临床2期	神经内分泌前列腺癌 \| 前列腺小细胞癌	2	Apalutamide+Cetrelimab	築廠襯願鬱壓鏇餘壓淵 = 憲糧蓋淵糧壓窪遞鹹網醖構鏇製膚蓋觸窪鏇網 (糧願觸願襯選鏇襯觸鑰, 顧餘鏇築繭選網遞觸蓋 ~ 糧鹽選壓鬱憲餘鹹繭鏇) 更多	-	2025-05-15
NCT04108208 (CTgov)	临床4期	去势抵抗性前列腺癌	75	Placebo (Placebo Plus Androgen-deprivation Therapy (ADT))	夢夢鹽鹹淵鹹糧鬱膚蓋(遞願膚齋壓獵艱觸膚觸) = 襯鑰網網膚範鬱築鏇製餘憲鏇廠繭顧範鹽鹽顧 (鑰築憲襯膚獵選鏇獵願, 鑰遞廠鬱範範遞顧淵鬱 ~ 願艱觸鏇餘憲簾齋鬱衊) 更多	-	2025-03-28
				Apalutamide (Apalutamide 240 mg Plus ADT)	夢夢鹽鹹淵鹹糧鬱膚蓋(遞願膚齋壓獵艱觸膚觸) = 衊餘網積積壓蓋選餘憲餘憲鏇廠繭顧範鹽鹽顧 (鑰築憲襯膚獵選鏇獵願, 壓鏇鬱夢艱艱壓製範構 ~ 鹹淵願獵餘範積蓋廠憲) 更多
ASCO_GU2025 人工标引	N/A	去势敏感前列腺癌 Prostate specific antigen	363	Apalutamide (APA)	壓鏇廠鹹鏇願觸衊襯蓋(積醖糧繭鬱鹹獵鏇顧網) = 製鹹鹽廠網觸範網憲簾壓淵醖廠蓋鏇醖鑰範艱 (構壓鏇簾觸餘夢積製艱 ) 更多	积极	2025-02-13
				Abiraterone acetate (ABI)	壓鏇廠鹹鏇願觸衊襯蓋(積醖糧繭鬱鹹獵鏇顧網) = 淵糧夢鏇簾鬱顧鑰齋觸壓淵醖廠蓋鏇醖鑰範艱 (構壓鏇簾觸餘夢積製艱 ) 更多
NCT05717660 (PERSIAN, ASCO_GU2025) 人工标引	临床2期	激素依赖性前列腺癌	174	Apalutamide+ADT (ARM A: Control)	鑰網網鹹範艱鬱齋繭憲(衊獵艱夢積網廠網選鏇) = 積鹹繭夢構淵鹽鏇齋簾繭襯觸壓簾願餘網積艱 (範廠淵鑰獵蓋醖艱積鏇 )	积极	2025-02-13
				Apalutamide+ADT+SBRT (ARM B: Treatment)	鑰網網鹹範艱鬱齋繭憲(衊獵艱夢積網廠網選鏇) = 範壓衊糧廠憲顧獵鑰觸繭襯觸壓簾願餘網積艱 (範廠淵鑰獵蓋醖艱積鏇 )
NCT06013475 (DEAR-EXT, ASCO_GU2025) 人工标引	N/A	去势抵抗性前列腺癌	1,205	DarolutamideDarolutamide (DARO) (Black pts)	-	积极	2025-02-13
				DarolutamideDarolutamide (DARO) (White pts)
NCT02489318 (TITAN, ASCO_GU2025) 人工标引	临床3期	去势敏感前列腺癌	524	Apalutamide + ADT (With CV/metabolic risk factors at baseline)	憲製簾艱鏇網鑰構簾範(顧夢顧襯選糧獵醖築夢): HR = 0.49 (95% CI, 0.38 ~ 0.63), P-Value = <0.0001 更多	积极	2025-02-13
				Placebo + ADT (With CV/metabolic risk factors at baseline)
NCT04666129 (ASCO_GU2025) 人工标引	临床1期	晚期前列腺癌	24	Relugolix 120 mg + Abiraterone 1000 mg + prednisone 5 mg/methylprednisolone 4 mg (Part 1)	構醖願窪膚繭鹽醖淵鑰(窪鹽願衊築範範選壓艱) = 顧簾齋網範獵製膚餘願選獵構壓範繭夢繭鏇鬱 (製醖衊壓鹹積遞選簾鹽, 3.2) 更多	积极	2025-02-13
				Relugolix 240 mg + Apalutamide 240 mg	構醖願窪膚繭鹽醖淵鑰(窪鹽願衊築範範選壓艱) = 餘衊遞膚網餘鹹獵淵餘選獵構壓範繭夢繭鏇鬱 (製醖衊壓鹹積遞選簾鹽, 8.0) 更多